USPTO serial 90112472
CELLCARTA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 18, 2024
- Examiner
- LEE, OLIVIA SUNMIN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with CELLCARTA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Montreal, Quebec, CA
Montreal, Quebec, CA
MONTREAL, QUEBEC, CA
MONTREAL, QUEBEC, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Keith Toms, Esq.
Keith Toms, Esq. MCCARTER & ENGLISH, LLP265 FRANKLIN STREETBOSTON, MA 02110-3113UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Scientific research and development; Medical research and development; Product research and development; Biochemical research and development; Pharmaceutical research and development services; Biomedical research and development services; Design and development of biochemical, pharmaceutical, and medical assays; Scientific and pharmaceutical research in the field of biomarker discovery; Scientific research and development in the fields of bioinformatics, biomarkers, genomics, proteomics, genotyping, pathology, histopathology; immune monitoring, and genetic profiling for research and development purposes; scientific research and development in the field of mass cytometry, cellular analysis, cell sorting, pathway phenotyping, and molecular surface profiling; custom design and development of chemical reagents and biochemical assays; medical laboratory services in the field of pathology; providing laboratory testing services in the fields of bioinformatics, biomarkers, genomics, proteomics, genotyping, pathology, histopathology; Conducting clinical trials for others; Conducting clinical trials for others in the fields of pharmaceutical, medical, and scientific research; Consulting services for others in the field of design, planning, and implementation project management of clinical trials; Conducting research and clinical trials for others in the fields of oncology, infectious diseases, autoimmune disorders, and allergies; Consulting services in the field of clinical trial research; Providing medical and scientific research information in the field of clinical trials; Research and development in the pharmaceutical and biotechnology fields; Laboratory research services relating to pharmaceuticals; Software as a service (SAAS) services featuring software for informatics, bioinformatics; software as a service (SAAS) services featuring software for clinical trial data acquisition, validation, and analysis; Software as a service (SAAS) services featuring software for cellular analysis, cell sorting, pathway phenotyping, and molecular surface profiling; Software as a service (SAAS) services featuring software for cell cytometry; Software as a service (SAAS) services featuring software for managing information related to clinical trials | ACTIVE | — |
| 044 | Genetic testing for medical purposes; Consulting services in the fields of diagnostic medical testing; Medical testing for diagnostic or treatment purposes; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; providing medical information and advice in the fields of pathology, pharmacology, and immunology; collection, organization, analysis, and reporting of medical data in connection with clinical and non-clinical trials and studies on pharmaceuticals and medical devices; immune monitoring, and genetic profiling for medical and diagnostic purposes | ACTIVE | — |
| 045 | Regulatory compliance consulting in the fields of pharmaceuticals and clinical diagnostics; Advice and consultancy on food, drug, and medical device regulatory matters; regulatory compliance consulting in the field of obtaining government authorization to market pharmaceuticals and medical device | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Caprion Biosciences, Inc.
- Other trademarks owned by Caprion Biosciences, Inc.
- Other trademarks owned by CELLCARTA BIOSCIENCES INC.
- Other trademarks owned by CELLCARTA BIOSCIENCES INC.
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named CELLCARTA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 18, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 18, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 13, 2024 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| May 13, 2024 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Mar 19, 2024 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Mar 18, 2024 | IUAF | USE AMENDMENT FILED | — |
| Mar 18, 2024 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Sep 20, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 19, 2023 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Sep 19, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Sep 12, 2023 | EXT5 | SOU EXTENSION 5 FILED | — |
| Sep 12, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 14, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 10, 2023 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Mar 10, 2023 | EXT4 | SOU EXTENSION 4 FILED | — |
| Mar 10, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 1, 2023 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Sep 20, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 16, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 16, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 16, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 17, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 15, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 15, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 15, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 18, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 16, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 16, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 16, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 16, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 19, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 19, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 30, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 14, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 11, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 11, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 11, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 11, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 9, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 9, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 9, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 8, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 17, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 17, 2020 | NWAP | NEW APPLICATION ENTERED | — |